0/60 2/56 OT 1 CT 2 Improvement, RR Dose (4d) Treatment Control Espitia-Hernandez 70% 0.30 12mg recov. other treatment 3 MD: minimal detail available currently 2 CT: study uses combined treatment 4 SC: study uses synthetic control arm Favors ivermectin Favors control population-based cohort Faisal (RCT) 68% 0.32 48mg no recov.